The neurodegenerative disorder Alzheimer's disease is becoming more prevalent in ageing populations worldwide. The identification of effective treatments will require a better understanding of the physiological mechanisms involved, and innovative approaches to drug development and evaluation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
Alzheimer's Research & Therapy Open Access 18 January 2024
-
TBX21, the Master regulator of the type 1 immune response, overexpresses in the leukocytes of peripheral blood in patients with late-onset Alzheimer’s disease
Immunity & Ageing Open Access 10 November 2023
-
Is blood-brain barrier a probable mediator of non-invasive brain stimulation effects on Alzheimer’s disease?
Communications Biology Open Access 14 April 2023
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
FURTHER READING
Alzheimer's Association 2009 Alzheimer's Disease Facts and Figures (2009).
Chin, J., Roberson, E. D. & Mucke, L. in Learning and Memory: A Comprehensive Reference Vol. 4 (ed. Byrne, J. H.) Ch. 15 (Academic, 2008).
Mahley, R. W., Weisgraber, K. H. & Huang, Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5644–5651 (2006).
Roberson, E. D. & Mucke, L. 100 years and counting: Prospects for defeating Alzheimer's disease. Science 314, 781–784 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author consults for Merck, has received research funding from Elan, and serves on the scientific advisory board of iPierian.
Additional information
See online at http://go.nature.com/phyLwm for more on neuroscience.
Rights and permissions
About this article
Cite this article
Mucke, L. Alzheimer's disease. Nature 461, 895–897 (2009). https://doi.org/10.1038/461895a
Published:
Issue Date:
DOI: https://doi.org/10.1038/461895a
This article is cited by
-
A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
Alzheimer's Research & Therapy (2024)
-
TBX21, the Master regulator of the type 1 immune response, overexpresses in the leukocytes of peripheral blood in patients with late-onset Alzheimer’s disease
Immunity & Ageing (2023)
-
Is blood-brain barrier a probable mediator of non-invasive brain stimulation effects on Alzheimer’s disease?
Communications Biology (2023)
-
Identifying β-secretase 1 (BACE1) inhibitors from plant-based compounds: an approach targeting Alzheimer’s therapeutics employing molecular docking and dynamics simulation
Molecular Diversity (2023)
-
Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders
Molecular Neurobiology (2023)